Can we use the canadian postmarketing spontaneous pharmacovigilance system for cardiovascular drug safety research? (2020)
- Authors:
- USP affiliated authors: SOUSA, FERNANDA RAPHAEL ESCOBAR GIMENES DE - EERP ; SILVEIRA, CAROLINA GALLI DA - EERP ; GONELLA, JENNIFER MIDIANI - EERP
- Unidade: EERP
- DOI: 10.1016/j.cjca.2020.07.166
- Subjects: FARMACOVIGILÂNCIA; MEDICAMENTO; FÁRMACOS (SISTEMA CARDIOVASCULAR)
- Language: Inglês
- Imprenta:
- Source:
- Título: Canadian Journal of Cardiology
- ISSN: 0828-282X
- Volume/Número/Paginação/Ano: v. 36, n. 10, suppl., p. S83-S84, 2020
- Conference titles: Canadian Cardiovascular Congress (CCC)
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
AKINOLA, Pelumi Samuel et al. Can we use the canadian postmarketing spontaneous pharmacovigilance system for cardiovascular drug safety research?. Canadian Journal of Cardiology. New York: Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.cjca.2020.07.166. Acesso em: 13 fev. 2026. , 2020 -
APA
Akinola, P. S., Silveira, C. G. da, Corbin, S., Lavallée, M., Thibault, M., Gonella, J. M., et al. (2020). Can we use the canadian postmarketing spontaneous pharmacovigilance system for cardiovascular drug safety research? Canadian Journal of Cardiology. New York: Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.cjca.2020.07.166 -
NLM
Akinola PS, Silveira CG da, Corbin S, Lavallée M, Thibault M, Gonella JM, Sousa FREG de, Leclerc J. Can we use the canadian postmarketing spontaneous pharmacovigilance system for cardiovascular drug safety research? [Internet]. Canadian Journal of Cardiology. 2020 ; 36( 10): S83-S84.[citado 2026 fev. 13 ] Available from: https://doi.org/10.1016/j.cjca.2020.07.166 -
Vancouver
Akinola PS, Silveira CG da, Corbin S, Lavallée M, Thibault M, Gonella JM, Sousa FREG de, Leclerc J. Can we use the canadian postmarketing spontaneous pharmacovigilance system for cardiovascular drug safety research? [Internet]. Canadian Journal of Cardiology. 2020 ; 36( 10): S83-S84.[citado 2026 fev. 13 ] Available from: https://doi.org/10.1016/j.cjca.2020.07.166 - Using data from the Canadian post-marketing spontaneous pharmacovigilance system for drug safety research: a feasibility study
- Reporting rates of opioid‑related adverse events since 1965 in Canada: a descriptive retrospective study
- Enfermeiros especialistas em diagnóstico por imagem [Editorial]: avanços e perspectivas para a enfermagem de prática avançada
- Impact of Vanessa's law on the reporting of serious adverse events: a retrospective study among antiplatelet users in a tertiary-care cardiology centre
- Causality assessment of adverse drug reaction: a narrative review to find the most exhaustive and easy-to-use tool in post-authorization settings
- Análise de eventos adversos a medicamentos provenientes do sistema on-line brasileiro e o impacto global da pandemia da COVID-19 nas notificações
- Are generic drugs used in cardiology as effective and safe as their brand-name counterparts? A systematic review and meta-analysis
- Processo de enfermagem na administração segura de medicamentos
- Risk factors for death in patients with sepsis in an intensive care unit
- Factors influencing the patient safety climate in intensive care units: cross-sectional study
Informações sobre o DOI: 10.1016/j.cjca.2020.07.166 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
